Jiaqi Huang1, Stephanie J Weinstein1, Kai Yu1, Satu Männistö2, Demetrius Albanes1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD. 2. Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Abstract
BACKGROUND: Epidemiologic data are inconsistent regarding the vitamin E-lung cancer association, and no study to our knowledge has examined serologic changes in vitamin E status in relation to subsequent risk. METHODS: In a cohort of 22 781 male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, we ascertained 3184 lung cancer cases during up to 28 years of observation. Cox proportional hazards models examined whether higher serum alpha-tocopherol concentrations at baseline, 3 years, or the interval change were associated with lower lung cancer risk. All statistical tests were two-sided. RESULTS: After adjustment for age, body mass index, smoking intensity and duration, serum total cholesterol, and trial intervention group, we found lower lung cancer risk in men with high baseline alpha-tocopherol (fifth quintile [Q5] vs Q1, hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.66 to 0.87, Ptrend < .001). A similar reduction in risk was seen for serum alpha-tocopherol at 3 years (Q5 vs Q1, HR = 0.78, 95% CI = 0.67 to 0.91, Ptrend = .004). The inverse risk association appeared stronger for younger men and those who had smoked fewer years but was similar across trial intervention groups. We also found reduced risk among men not supplemented with vitamin E who had a lower serum alpha-tocopherol at baseline and greater increases in concentrations at 3 years (third tertile vs first tertile of serum alpha-tocopherol change, HR = 0.74, 95% CI = 0.59 to 0.91, P = .005). CONCLUSIONS: Higher vitamin E status, as measured by serum alpha-tocopherol concentration, as well as repletion of a low vitamin E state, was related to decreased lung cancer risk during a 28-year period. Our findings provide evidence supporting the importance of adequate physiological vitamin E status for lung cancer risk reduction. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the United States.
BACKGROUND: Epidemiologic data are inconsistent regarding the vitamin E-lung cancer association, and no study to our knowledge has examined serologic changes in vitamin E status in relation to subsequent risk. METHODS: In a cohort of 22 781 male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, we ascertained 3184 lung cancer cases during up to 28 years of observation. Cox proportional hazards models examined whether higher serum alpha-tocopherol concentrations at baseline, 3 years, or the interval change were associated with lower lung cancer risk. All statistical tests were two-sided. RESULTS: After adjustment for age, body mass index, smoking intensity and duration, serum total cholesterol, and trial intervention group, we found lower lung cancer risk in men with high baseline alpha-tocopherol (fifth quintile [Q5] vs Q1, hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.66 to 0.87, Ptrend < .001). A similar reduction in risk was seen for serum alpha-tocopherol at 3 years (Q5 vs Q1, HR = 0.78, 95% CI = 0.67 to 0.91, Ptrend = .004). The inverse risk association appeared stronger for younger men and those who had smoked fewer years but was similar across trial intervention groups. We also found reduced risk among men not supplemented with vitamin E who had a lower serum alpha-tocopherol at baseline and greater increases in concentrations at 3 years (third tertile vs first tertile of serum alpha-tocopherol change, HR = 0.74, 95% CI = 0.59 to 0.91, P = .005). CONCLUSIONS: Higher vitamin E status, as measured by serum alpha-tocopherol concentration, as well as repletion of a low vitamin E state, was related to decreased lung cancer risk during a 28-year period. Our findings provide evidence supporting the importance of adequate physiological vitamin E status for lung cancer risk reduction. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the United States.
Authors: D Albanes; O P Heinonen; P R Taylor; J Virtamo; B K Edwards; M Rautalahti; A M Hartman; J Palmgren; L S Freedman; J Haapakoski; M J Barrett; P Pietinen; N Malila; E Tala; K Liippo; E R Salomaa; J A Tangrea; L Teppo; F B Askin; E Taskinen; Y Erozan; P Greenwald; J K Huttunen Journal: J Natl Cancer Inst Date: 1996-11-06 Impact factor: 13.506
Authors: P Borel; N Mekki; Y Boirie; A Partier; P Grolier; M C Alexandre-Gouabau; B Beaufrere; M Armand; D Lairon; V Azais-Braesco Journal: Eur J Clin Invest Date: 1997-10 Impact factor: 4.686
Authors: H B Stähelin; K F Gey; M Eichholzer; E Lüdin; F Bernasconi; J Thurneysen; G Brubacher Journal: Am J Epidemiol Date: 1991-04-15 Impact factor: 4.897
Authors: Meira Epplein; Adrian A Franke; Robert V Cooney; J Steven Morris; Lynne R Wilkens; Marc T Goodman; Suzanne P Murphy; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-16 Impact factor: 4.254
Authors: Scott M Lippman; Eric A Klein; Phyllis J Goodman; M Scott Lucia; Ian M Thompson; Leslie G Ford; Howard L Parnes; Lori M Minasian; J Michael Gaziano; Jo Ann Hartline; J Kellogg Parsons; James D Bearden; E David Crawford; Gary E Goodman; Jaime Claudio; Eric Winquist; Elise D Cook; Daniel D Karp; Philip Walther; Michael M Lieber; Alan R Kristal; Amy K Darke; Kathryn B Arnold; Patricia A Ganz; Regina M Santella; Demetrius Albanes; Philip R Taylor; Jeffrey L Probstfield; T J Jagpal; John J Crowley; Frank L Meyskens; Laurence H Baker; Charles A Coltman Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: Suzanne M Jeurnink; Martine M Ros; Max Leenders; Franzel J B van Duijnhoven; Peter D Siersema; Eugene H J M Jansen; Carla H van Gils; Marije F Bakker; Kim Overvad; Nina Roswall; Anne Tjønneland; Marie-Christine Boutron-Ruault; Antoine Racine; Claire Cadeau; Verena Grote; Rudolf Kaaks; Krasimira Aleksandrova; Heiner Boeing; Antonia Trichopoulou; Vasiliki Benetou; Elisavet Valanou; Domenico Palli; Vittorio Krogh; Paolo Vineis; Rosario Tumino; Amalia Mattiello; Elisabete Weiderpass; Guri Skeie; José María Huerta Castaño; Eric J Duell; Aurelio Barricarte; Esther Molina-Montes; Marcial Argüelles; Mire Dorronsoro; Dorthe Johansen; Björn Lindkvist; Malin Sund; Francesca L Crowe; Kay-Tee Khaw; Mazda Jenab; Veronika Fedirko; E Riboli; H B Bueno-de-Mesquita Journal: Int J Cancer Date: 2014-09-17 Impact factor: 7.396
Authors: Junyi Xin; Xia Jiang; Shuai Ben; Qianyu Yuan; Li Su; Zhengdong Zhang; David C Christiani; Mulong Du; Meilin Wang Journal: BMC Med Date: 2022-05-11 Impact factor: 11.150